Author

A. Drilon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

B. M. Baker· 1 shared B. Weigelt· 1 shared C. A. Klebanoff· 1 shared C. Bandlamudi· 1 shared C. Keddy· 1 shared C. Z. Beach· 1 shared D. A. Scheinberg· 1 shared D. Betel· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

B. M. Baker

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers

R. Thawani, M. Repetto, C. Keddy, K. Nicholson, K. Jones, K. Nusser, C. Z. Beach, G. Harada, A. Drilon, M. A. Davare

This study shows that type II TKIs cabozantinib and merestinib, and type I FLT3 inhibitor gilteritinib, inhibit ROS1 L2086F mutant kinase, overcoming resistance to type I TKIs in ROS1 fusion-positive cancers.

bioRxiv · Jan 16, 2024Cancer Biology

Immunogenicity of a public neoantigen derived from mutated PIK3CA

S. S. Chandran, J. Ma, M. G. Klatt, F. Dundar, C. Bandlamudi, P. C. Razavi, H. Y. Wen, B. Weigelt, P. Zumbo, S. N. Fu, L. B. Banks, W. D. Bestman, A. Drilon, D. Betel, D. A. Scheinberg, , C. A. Klebanoff

The paper investigates the immunogenicity of a public neoantigen derived from mutated PIK3CA, showing it is recognized by T cells and presents a framework for immunotherapy.

bioRxiv · Apr 8, 2021 · PreprintImmunology